An MD Anderson team led by Amir Jazaeri, MD, takes a pioneering approach to finding residual ovarian cancer cells.

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 ...

Robert L. Ferris, MD, PhD, editor-in-chief of Targeted Therapies in Oncology, discusses his monthly column in this episode of ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating ...